“The combination of carboplatin and nab-paclitaxel demonstrates promising efficacy with tolerable toxicity in patients with non-small cell lung cancer (NSCLC) ineligible for therapy with bevacizumab,” said Gregory A. Otterson, MD, professor of internal medicine, co-director of the thoracic oncology program and associate director of the hematology and medical oncology fellowship program at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, Ohio.
Obese, white women may be less likely than their normal-weight peers and African-Americans of any weight or gender to obtain colon cancer screening tests, according to a new study by Johns Hopkins researchers.
How do healthcare providers react to medication alerts generated by electronic medical record systems?
To learn about the strengths and weaknesses of electronic medication alerts, a study by Regenstrief Institute and US Department of Veterans Affairs investigators involved observing providers as they treated patients. The study appears in the April 2012 issue of the International Journal of Medical Informatics.
The FDA is alerting US medical practices of another counterfeit cancer drug originating from a foreign source.
According to FDA lab tests, an imitation version of Roche’s Altuzan 400 mg/16 mL (bevacizumab), a drug not approved by the FDA for use in the US, is actually in the country and contains no active ingredient.
The counterfeit Altuzan and other unapproved products were obtained through foreign sources, in particular from Richards Pharma, also known as Richards Services, Warwick Healthcare Solutions, or Ban Dune Marketing Inc (BDMI).
The University of Southern California (USC) Norris Comprehensive Cancer Center is part of the Keck School of Medicine and is designated by the National Cancer Institute as one of the nation’s 40 comprehensive cancer centers. Located in Los Angeles, the USC Norris Comprehensive Cancer Center serves as a regional and national resource for cancer treatment, research, prevention, and education. Read More ›
Fear of genetic discrimination is often a stated barrier to referral to genetic counseling services and to willingness to undergo genetic testing.1,2 As a result, when the Genetic Information Nondiscrimination Act (GINA) was signed almost 4 years ago by President George W. Bush, many felt that this would be the panacea for individuals concerned about discrimination. GINA was the first federal legislation providing protections against genetic discrimination by health insurers and employers. Read More ›
“Are you crazy, yet?”
A new quantitative imaging bone biomarker has been identified that can assess response and is prognostic for survival in men with metastatic castration-resistant prostate cancer (mCRPC).
With this issue of The Oncology Nurse-APN/PA (TON), we cover everything from issues related to genetic discrimination to how a patient feels about her interaction with a doctor. Cristi Radford and Anya Prince provide specific information about the 2008 Genetic Info Information Nondiscrimination Act so oncology nurses can help their patients navigate the concerns about their medical records and health insurance coverage. Read More ›
To sign up for our newsletter or print publications, please enter your contact information below.
